These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 12005110)

  • 41. The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study.
    Leinonen E; Niemi H
    Nord J Psychiatry; 2007; 61(2):109-14. PubMed ID: 17454725
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Re: citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients.
    Rostami Z; Einollahi B
    Iran J Kidney Dis; 2013 Jan; 7(1):73-4. PubMed ID: 23314148
    [No Abstract]   [Full Text] [Related]  

  • 43. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
    Wade AG; Toumi I; Hemels ME
    Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quality of life measurement in antidepressant trials. Is there an added value?
    De Fruyt J; Demyttenaere K
    Psychother Psychosom; 2009; 78(4):212-9. PubMed ID: 19401621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study.
    Yu AP; Xie J; Bensimon A; Parikh K; Wu EQ; Ben-Hamadi R; Blum S; Haim Erder M
    J Med Econ; 2010; 13(4):599-609. PubMed ID: 20879834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Citalopram-induced hallucinations and delusions in a young adult.
    Capaldi VF; Carr RB
    Gen Hosp Psychiatry; 2010; 32(6):648.e1-3. PubMed ID: 21112465
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Citalopram in children and adolescents with depression or anxiety.
    Baumgartner JL; Emslie GJ; Crismon ML
    Ann Pharmacother; 2002 Nov; 36(11):1692-7. PubMed ID: 12398561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. S-enantiomer of the selective serotonin reuptake inhibitor citalopram compared with racemate citalopram (S+R).
    Håkanson R
    Pharmacol Toxicol; 2001 Oct; 89(4):153-5. PubMed ID: 11881963
    [No Abstract]   [Full Text] [Related]  

  • 51. Tardive dyskinesia associated with long-term administration of escitalopram and itopride in major depressive disorder.
    Park YM; Lee HJ; Kang SG; Choo CS; Cho JH
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):380-1. PubMed ID: 19121360
    [No Abstract]   [Full Text] [Related]  

  • 52. Escitalopram: a review of its use in the management of anxiety disorders.
    Dhillon S; Scott LJ; Plosker GL
    CNS Drugs; 2006; 20(9):763-90. PubMed ID: 16953656
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of Raynaud's phenomenon with escitalopram.
    Buecking A; Rougemont E; Fabio Zullino D
    Int J Neuropsychopharmacol; 2005 Jun; 8(2):307-8. PubMed ID: 15569398
    [No Abstract]   [Full Text] [Related]  

  • 54. Withdrawal symptoms of trifluoperazine.
    Chakraborty R; Chatterjee A; Chaudhury S
    J Neuropsychiatry Clin Neurosci; 2008; 20(4):495-6. PubMed ID: 19196940
    [No Abstract]   [Full Text] [Related]  

  • 55. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.
    Kraus MR; Schäfer A; Schöttker K; Keicher C; Weissbrich B; Hofbauer I; Scheurlen M
    Gut; 2008 Apr; 57(4):531-6. PubMed ID: 18079286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B; Andersen HF; Dolberg OT
    Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Escitalopram-induced subclinical hypothyroidism. A case report.
    Mazokopakis EE; Karefilakis CM; Starakis IK
    Hormones (Athens); 2012; 11(1):101-3. PubMed ID: 22450350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Depression among dialysis patients: barriers to good care.
    Farrokhi F
    Iran J Kidney Dis; 2012 Nov; 6(6):403-6. PubMed ID: 23146976
    [No Abstract]   [Full Text] [Related]  

  • 59. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
    Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
    Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renal failure in a depressed adolescent on escitalopram.
    Miriyala K; Coffey B
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):405-8. PubMed ID: 18759653
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.